Endo International (ENDP) Gains on Acerus Deal

Endo International plc ENDP shares hiked 2.5% to $16.94, on word Acerus Pharmaceuticals completed the NATESTO® U.S. transition from an affiliate of Endo back to Acerus, and subsequently to Aytu BioScience, Inc. Aytu will now assume responsibility for the U.S. commercialization of NATESTO®, the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism. Share volume was five million, compared to an all-day average of 10 million
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!